I-MAB (IMAB) has released an update.
I-Mab, a U.S.-based global biotech company, has announced robust progress in its cancer treatment pipeline, including a new IND clearance and a clinical collaboration with Bristol Myers Squibb. The company has a strong financial position with $207.5 million in cash, a completed divestiture of its China operations, and a cash runway extending into 2027. Strategic advancements such as new leadership appointments and promising clinical trial results position I-Mab for potential milestones in the coming year.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
